We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS and Pfizer Win Appeals Court Ruling on Blockbuster Eliquis
BMS and Pfizer Win Appeals Court Ruling on Blockbuster Eliquis
The U.S. Court of Appeals for the Federal Circuit has upheld a prior victory for Bristol Myers Squibb and Pfizer covering two Eliquis (apixaban) patents, positioning the companies to keep exclusivity in the U.S. for the blockbuster oral anticoagulant until April 1, 2028.